Coagulofibrinolytic assessment of effects of bezafibrate on hypertriglyceridemia in postmenopausal women.
The present study investigates the effect of bezafibrate on lipid levels and coagulofibrinolytic factors. Subjects enrolled in the study included 124 postmenopausal women with hypertriglyceridemia. We examined the levels of tissue plasminogen activator (t-PA), plasminogen activator inhibitor type-1 (PAI-1), and blood coagulation factors VII and X as parameters of coagulofibrinolysis. After 12 weeks of bezafibrate therapy, mean serum triglyceride (TG) and remnant-like particle lipoprotein cholesterol (RLP-C) levels significantly decreased from baseline. Activated factor X levels decreased significantly by 11.3% (P < 0.01) and the ratio of tPA/PAI-1 (0.146+/-0.07) increased significantly by 37.7% from baseline (P < 0.05). The rates of change in activated factor VII and PAI-1 showed a significant positive correlate with the rates of change in TG and RLP-C (P = 0.001). These present findings suggest that bezafibrate improves triglyceride-rich lipoprotein metabolism and coagulofibrinolytic activity by increasing fibrinolysis in postmenopausal women with hypertriglyceridemia.
Ushiroyama
T
T
Department of Obstetrics and Gynecology, Osaka Medical College, Takatsuki, Japan. gyn003@poh.osaka-med.ac.jp
Ikeda
A
A
Higashio
S
S
Ueki
M
M
D001629:Bezafibrate / Q000494:pharmacology* / Q000627:therapeutic use; D005260:Female; D005342:Fibrinolysis / Q000187:drug effects*; D006801:Humans; D015228:Hypertriglyceridemia / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology*; D000960:Hypolipidemic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D008875:Middle Aged; D017698:Postmenopause
D000960:Hypolipidemic Agents; D001629:Bezafibrate